The New England Journal of Medicine, ISSN 0028-4793, 09/2016, Volume 375, Issue 9, pp. 830 - 839
In this report involving 1763 HIV-1 serodiscordant couples, the suppression of HIV-1 in the infected partner significantly decreased the transmission of...
VIRAL LOAD | POPULATION | MEDICINE, GENERAL & INTERNAL | INITIATION | HPTN 052 | RANDOMIZED-TRIAL | INFECTION | SERODISCORDANT COUPLES | CHALLENGES | HIV Infections - prevention & control | Anti-Retroviral Agents - therapeutic use | Follow-Up Studies | HIV Seropositivity | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | HIV-1 - genetics | Disease Transmission, Infectious - prevention & control | Young Adult | Intention to Treat Analysis | Adult | Female | HIV Infections - transmission | Sexual Partners | Prevention | Antiviral agents | Usage | Care and treatment | HIV (Viruses) | Antiretroviral drugs | Hypersensitivity | Clinical trials | Data processing | Antiretroviral therapy | CD4 antigen | Disease prevention | Disease transmission | Infectious diseases | Motivation | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Drug therapy | Sexual partners
VIRAL LOAD | POPULATION | MEDICINE, GENERAL & INTERNAL | INITIATION | HPTN 052 | RANDOMIZED-TRIAL | INFECTION | SERODISCORDANT COUPLES | CHALLENGES | HIV Infections - prevention & control | Anti-Retroviral Agents - therapeutic use | Follow-Up Studies | HIV Seropositivity | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | HIV-1 - genetics | Disease Transmission, Infectious - prevention & control | Young Adult | Intention to Treat Analysis | Adult | Female | HIV Infections - transmission | Sexual Partners | Prevention | Antiviral agents | Usage | Care and treatment | HIV (Viruses) | Antiretroviral drugs | Hypersensitivity | Clinical trials | Data processing | Antiretroviral therapy | CD4 antigen | Disease prevention | Disease transmission | Infectious diseases | Motivation | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Drug therapy | Sexual partners
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2011, Volume 365, Issue 6, pp. 493 - 505
In this large, international study of HIV-1–serodiscordant couples, the receipt of antiretroviral therapy by the infected partner decreased transmission to the...
MORTALITY | MEDICINE, GENERAL & INTERNAL | TRANSMISSION | COUNTRIES | INITIATION | MALAWI | IMMUNODEFICIENCY-VIRUS TYPE-1 | RETHINKING | HIV-1-INFECTED PATIENTS | COHORT | UGANDA | HIV-1 | HIV Infections - prevention & control | Anti-Retroviral Agents - therapeutic use | HIV Seropositivity | Humans | Anti-Retroviral Agents - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Spouses | Treatment Outcome | Disease Progression | Disease Transmission, Infectious - prevention & control | Young Adult | Adolescent | Adult | Female | HIV Infections - drug therapy | HIV Infections - transmission | Sexual Partners | Drug Therapy, Combination | Antiviral agents | Usage | Patient outcomes | Management | Drug therapy | Health aspects | HIV infection | Public health | Fees & charges | Antiretroviral drugs | Couples | Enrollments | Laboratories | Hypersensitivity | Sexual transmission | Infections | Grants | Antiretroviral therapy | CD4 antigen | Disease prevention | Studies | Infectious diseases | Disease transmission | Tuberculosis | Human immunodeficiency virus--HIV | Counseling | Population
MORTALITY | MEDICINE, GENERAL & INTERNAL | TRANSMISSION | COUNTRIES | INITIATION | MALAWI | IMMUNODEFICIENCY-VIRUS TYPE-1 | RETHINKING | HIV-1-INFECTED PATIENTS | COHORT | UGANDA | HIV-1 | HIV Infections - prevention & control | Anti-Retroviral Agents - therapeutic use | HIV Seropositivity | Humans | Anti-Retroviral Agents - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Spouses | Treatment Outcome | Disease Progression | Disease Transmission, Infectious - prevention & control | Young Adult | Adolescent | Adult | Female | HIV Infections - drug therapy | HIV Infections - transmission | Sexual Partners | Drug Therapy, Combination | Antiviral agents | Usage | Patient outcomes | Management | Drug therapy | Health aspects | HIV infection | Public health | Fees & charges | Antiretroviral drugs | Couples | Enrollments | Laboratories | Hypersensitivity | Sexual transmission | Infections | Grants | Antiretroviral therapy | CD4 antigen | Disease prevention | Studies | Infectious diseases | Disease transmission | Tuberculosis | Human immunodeficiency virus--HIV | Counseling | Population
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 12, pp. 1343 - 1343
 The authors are mostly from the UK, with limited representation from the US and South Africa. [...]the volume has a bent towards Public Health England and...
Infectious Disease | Infectious diseases | Acquired immune deficiency syndrome--AIDS | Mortality | Severe acute respiratory syndrome | Handbooks | Infections | Epidemiology | Public health
Infectious Disease | Infectious diseases | Acquired immune deficiency syndrome--AIDS | Mortality | Severe acute respiratory syndrome | Handbooks | Infections | Epidemiology | Public health
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2019, Volume 14, Issue 3, p. e0213357
Introduction Prescription drug abuse is a major public health problem in rural and suburban areas of the United States, however its emergence in large urban...
TRANSITION | HEROIN USE | INITIATION | PREDICTORS | MULTIDISCIPLINARY SCIENCES | DISEASE | OPIOIDS | PEOPLE | COHORT | Drugs | Intravenous drug abuse | Analysis | Mortality | Dosage and administration | Research | Maryland | Prevalence studies (Epidemiology) | Drug abuse | Suburban areas | Drug overdose | Epidemiology | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Opioids | Trends | Public health | Drug use | Vital statistics | Medical research | Narcotics | Rural areas | Urban areas | Needle exchange programs | Vital signs | Injection | Urban environments | Disease prevention | Prescription drugs | Census of Population | Cocaine | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
TRANSITION | HEROIN USE | INITIATION | PREDICTORS | MULTIDISCIPLINARY SCIENCES | DISEASE | OPIOIDS | PEOPLE | COHORT | Drugs | Intravenous drug abuse | Analysis | Mortality | Dosage and administration | Research | Maryland | Prevalence studies (Epidemiology) | Drug abuse | Suburban areas | Drug overdose | Epidemiology | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Opioids | Trends | Public health | Drug use | Vital statistics | Medical research | Narcotics | Rural areas | Urban areas | Needle exchange programs | Vital signs | Injection | Urban environments | Disease prevention | Prescription drugs | Census of Population | Cocaine | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 4, pp. 281 - 290
Summary Background Use of antiretroviral treatment for HIV-1 infection has decreased AIDS-related morbidity and mortality and prevents sexual transmission of...
Infectious Disease | MORTALITY | INFECTIOUS DISEASES | THERAPY | EVENTS | ADULTS | AIDS | HIV-1-INFECTED PATIENTS | HIV-1 | Humans | Male | Young Adult | Acquired Immunodeficiency Syndrome - immunology | Neoplasms - complications | Cardiovascular Diseases - complications | Time Factors | Liver Diseases - complications | Adult | Female | Diabetes Mellitus, Type 2 - complications | Drug Administration Schedule | AIDS-Related Opportunistic Infections - immunology | AIDS-Related Opportunistic Infections - drug therapy | Kaplan-Meier Estimate | Proportional Hazards Models | CD4 Lymphocyte Count | Acquired Immunodeficiency Syndrome - drug therapy | Disease Progression | Tuberculosis, Pulmonary - diagnosis | Anti-Retroviral Agents - administration & dosage | Intention to Treat Analysis | Kidney Failure, Chronic - complications | Acquired Immunodeficiency Syndrome - complications | Antiviral agents | Mortality | Public health | Bacterial infections | Acquired immune deficiency syndrome--AIDS | Drug therapy | Human immunodeficiency virus--HIV
Infectious Disease | MORTALITY | INFECTIOUS DISEASES | THERAPY | EVENTS | ADULTS | AIDS | HIV-1-INFECTED PATIENTS | HIV-1 | Humans | Male | Young Adult | Acquired Immunodeficiency Syndrome - immunology | Neoplasms - complications | Cardiovascular Diseases - complications | Time Factors | Liver Diseases - complications | Adult | Female | Diabetes Mellitus, Type 2 - complications | Drug Administration Schedule | AIDS-Related Opportunistic Infections - immunology | AIDS-Related Opportunistic Infections - drug therapy | Kaplan-Meier Estimate | Proportional Hazards Models | CD4 Lymphocyte Count | Acquired Immunodeficiency Syndrome - drug therapy | Disease Progression | Tuberculosis, Pulmonary - diagnosis | Anti-Retroviral Agents - administration & dosage | Intention to Treat Analysis | Kidney Failure, Chronic - complications | Acquired Immunodeficiency Syndrome - complications | Antiviral agents | Mortality | Public health | Bacterial infections | Acquired immune deficiency syndrome--AIDS | Drug therapy | Human immunodeficiency virus--HIV
Journal Article
PLoS Medicine, ISSN 1549-1277, 08/2012, Volume 9, Issue 8, p. e1001290
Background: Antiretroviral regimens with simplified dosing and better safety are needed to maximize the efficiency of antiretroviral delivery in...
LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | THERAPY | DIDANOSINE | LOW-DOSE RITONAVIR | EFAVIRENZ | EMTRICITABINE | RETROVIRAL-NAIVE PATIENTS | INFECTION | ATAZANAVIR | ADVERSE EVENTS | Anti-HIV Agents - pharmacology | Coinfection | Follow-Up Studies | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | Treatment Outcome | Withholding Treatment | Pregnancy | HIV Infections - microbiology | Time Factors | Internationality | Mycobacterium tuberculosis - physiology | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Drug Therapy, Combination | Medicine | Antiviral agents | Care and treatment | Safety and security measures | Practice | Research | HIV (Viruses) | Health aspects | Clinical trials | Medical research | Hospitals | Acquired immune deficiency syndrome--AIDS | Drug therapy | Human immunodeficiency virus--HIV | HIV | Acquired immune deficiency syndrome | AIDS | Human immunodeficiency virus
LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | THERAPY | DIDANOSINE | LOW-DOSE RITONAVIR | EFAVIRENZ | EMTRICITABINE | RETROVIRAL-NAIVE PATIENTS | INFECTION | ATAZANAVIR | ADVERSE EVENTS | Anti-HIV Agents - pharmacology | Coinfection | Follow-Up Studies | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | Treatment Outcome | Withholding Treatment | Pregnancy | HIV Infections - microbiology | Time Factors | Internationality | Mycobacterium tuberculosis - physiology | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Drug Therapy, Combination | Medicine | Antiviral agents | Care and treatment | Safety and security measures | Practice | Research | HIV (Viruses) | Health aspects | Clinical trials | Medical research | Hospitals | Acquired immune deficiency syndrome--AIDS | Drug therapy | Human immunodeficiency virus--HIV | HIV | Acquired immune deficiency syndrome | AIDS | Human immunodeficiency virus
Journal Article